722 related articles for article (PubMed ID: 18783534)
41. Placebo response in the treatment of women's sexual dysfunctions: a review and commentary.
Bradford A; Meston CM
J Sex Marital Ther; 2009; 35(3):164-81. PubMed ID: 19360517
[TBL] [Abstract][Full Text] [Related]
42. The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review.
Uloko M; Rahman F; Puri LI; Rubin RS
Int J Impot Res; 2022 Nov; 34(7):635-641. PubMed ID: 36198811
[TBL] [Abstract][Full Text] [Related]
43. [The Role of Testosterone in The Improvement of Sexual Desire in Postmenopausal Women: An Evidence-Based Clinical Review].
Gouveia M; Sanches R; Andrade S; Carmona S; Ferreira C
Acta Med Port; 2018 Nov; 31(11):680-690. PubMed ID: 30521462
[TBL] [Abstract][Full Text] [Related]
44. Systemic testosterone for the treatment of female sexual interest and arousal disorder (FSIAD) in the postmenopause.
Ribera Torres L; Anglès-Acedo S; López Chardi L; Mension Coll E; Castelo-Branco C
Gynecol Endocrinol; 2024 Dec; 40(1):2364220. PubMed ID: 38913119
[TBL] [Abstract][Full Text] [Related]
45. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.
Derogatis LR; Komer L; Katz M; Moreau M; Kimura T; Garcia M; Wunderlich G; Pyke R;
J Sex Med; 2012 Apr; 9(4):1074-85. PubMed ID: 22248038
[TBL] [Abstract][Full Text] [Related]
46. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk?
Schover LR
Fertil Steril; 2008 Jul; 90(1):129-40. PubMed ID: 18023435
[TBL] [Abstract][Full Text] [Related]
47. [Testosterone therapy in female hypoactive sexual desire disorder].
Meyer P
Rev Med Suisse; 2016 Mar; 12(510):540-3. PubMed ID: 27149714
[TBL] [Abstract][Full Text] [Related]
48. Androgen therapy in women, beyond libido.
Davis SR
Climacteric; 2013 Aug; 16 Suppl 1():18-24. PubMed ID: 23647457
[TBL] [Abstract][Full Text] [Related]
49. The clinical use of androgens in female sexual disorders.
Davis SR
J Sex Marital Ther; 1998; 24(3):153-63. PubMed ID: 9670121
[TBL] [Abstract][Full Text] [Related]
50. Androgens and Psychosocial Factors Related to Sexual Dysfunctions in Premenopausal Women
Wåhlin-Jacobsen S; Kristensen E; Pedersen AT; Laessøe NC; Cohen AS; Hougaard DM; Lundqvist M; Giraldi A
J Sex Med; 2017 Mar; 14(3):366-379. PubMed ID: 28117267
[TBL] [Abstract][Full Text] [Related]
51. Androgen Therapy in Women.
Vegunta S; Kling JM; Kapoor E
J Womens Health (Larchmt); 2020 Jan; 29(1):57-64. PubMed ID: 31687883
[TBL] [Abstract][Full Text] [Related]
52. The role of androgens in hormone replacement therapy.
Johnson CE; Berman JR
Expert Opin Pharmacother; 2005 Sep; 6(11):1815-31. PubMed ID: 16144503
[TBL] [Abstract][Full Text] [Related]
53. Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study.
Portman DJ; Brown L; Yuan J; Kissling R; Kingsberg SA
J Sex Med; 2017 Jun; 14(6):834-842. PubMed ID: 28583342
[TBL] [Abstract][Full Text] [Related]
54. The prevalence of hypoactive sexual desire disorder in surgically menopausal women: an epidemiological study of women in four European countries.
Graziottin A; Koochaki PE; Rodenberg CA; Dennerstein L
J Sex Med; 2009 Aug; 6(8):2143-53. PubMed ID: 19453880
[TBL] [Abstract][Full Text] [Related]
55. Needs assessment.
J Sex Med; 2008 Sep; 5 Suppl 4():179. PubMed ID: 18783532
[No Abstract] [Full Text] [Related]
56. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder.
Derogatis L; Clayton A; Lewis-D'Agostino D; Wunderlich G; Fu Y
J Sex Med; 2008 Feb; 5(2):357-64. PubMed ID: 18042215
[TBL] [Abstract][Full Text] [Related]
57. Androgens and Female Sexual Function and Dysfunction--Findings From the Fourth International Consultation of Sexual Medicine.
Davis SR; Worsley R; Miller KK; Parish SJ; Santoro N
J Sex Med; 2016 Feb; 13(2):168-78. PubMed ID: 26953831
[TBL] [Abstract][Full Text] [Related]
58. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues.
Poels S; Bloemers J; van Rooij K; Goldstein I; Gerritsen J; van Ham D; van Mameren F; Chivers M; Everaerd W; Koppeschaar H; Olivier B; Tuiten A
J Sex Med; 2013 Mar; 10(3):810-23. PubMed ID: 23130748
[TBL] [Abstract][Full Text] [Related]
59. Clinical review: Controversies regarding transdermal androgen therapy in postmenopausal women.
Basaria S; Dobs AS
J Clin Endocrinol Metab; 2006 Dec; 91(12):4743-52. PubMed ID: 16984993
[TBL] [Abstract][Full Text] [Related]
60. Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms.
van Rooij K; Poels S; Bloemers J; Goldstein I; Gerritsen J; van Ham D; van Mameren F; Chivers M; Everaerd W; Koppeschaar H; Olivier B; Tuiten A
J Sex Med; 2013 Mar; 10(3):824-37. PubMed ID: 23130675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
